Trials / Completed
CompletedNCT00239005
Enteric-Coated Mycophenolate Sodium on Quality of Life in Patients With Gastrointestinal Symptoms Related to Mycophenolate Mofetil Therapy After Kidney Transplantation
A Study of the Effect of Conversion to Enteric-Coated Mycophenolate Sodium (EC-MPS) on Quality of Life in Patients With Gastrointestinal (GI) Symptoms Related to Mycophenolate Mofetil Therapy After Kidney Transplantation (MYQOL)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 134 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This open, multi-center randomized controlled study is designed to investigate the quality of life in patients with mycophenolate mofetil (MMF)-induced gastrointestinal (GI) adverse events after converting to enteric-coated mycophenolate sodium (EC-MPS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enteric-Coated Mycophenolate Sodium (EC-MPS) | |
| DRUG | Mycophenolate Mofetil (MMF) |
Timeline
- Start date
- 2005-09-01
- Primary completion
- 2008-03-01
- First posted
- 2005-10-14
- Last updated
- 2017-03-30
- Results posted
- 2011-03-24
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00239005. Inclusion in this directory is not an endorsement.